Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults and provides relief from headache pain and associated symptoms.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxalt (rizatriptan) belongs to the triptan class and is used to treat acute migraine episodes.

- Migraine (with aura): relieves headache pain and associated neurological symptoms. - Migraine (without aura): reduces intensity of headache and associated nausea. - Acute migraine attack: provides rapid relief of pain, photophobia and phonophobia.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in the fingers or face - Dizziness or light‑headedness - Fatigue or drowsiness - Nausea or abdominal pain - Dry mouth

Serious or Rare Side Effects: - Coronary artery vasospasm or myocardial ischemia - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reactions (anaphylaxis, angioedema) - Hypertension or hypertensive crisis - Cardiac arrhythmias - Stroke or transient ischemic attack

Before using Maxalt, consider the following safety measures.

- Cardiovascular disease: avoid if you have uncontrolled heart disease or recent myocardial infarction. - Hepatic impairment: dose may need adjustment in moderate to severe liver dysfunction. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy: limited data; use only if potential benefit outweighs risk. - Lactation: unknown excretion in breast milk; consult a healthcare professional. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Rizatriptan can interact with several medication classes; monitoring is essential.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may precipitate serotonin toxicity. - Ergot alkaloids (e.g., ergotamine): additive vasoconstriction. - Other triptans: risk of excessive vasoconstriction. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise rizatriptan plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure effects. - Diuretics: monitor electrolyte balance. - Oral contraceptives: may alter metabolism. - Antihistamines: may increase sedation. - Alcohol: can enhance dizziness and drowsiness.